Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05190341
Other study ID # 221063
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date January 31, 2022
Est. completion date January 1, 2023

Study information

Verified date December 2021
Source Madigan Army Medical Center
Contact Bruce Pier, MD
Phone 253-968-3276
Email bruce.d.pier3.mil@mail.mil
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Hysterosalpingogram (HSG) testing is a vital part of the workup for infertility patients. It is often noted to be biggest pain that patients undergo during the workup. Several studies have attempted to find a therapy that reduces pain, with non-steroidal anti-inflammatory drugs such as oral ibuprofen the current mainstay. Our study attempts to determine which of the following NSAIDS is best at reducing pain associated with the HSG procedure: oral ibuprofen versus oral ketorolac .


Description:

Describe step-by-step how the study will be conducted from beginning to end 1. After IRB approval, the research pharmacist will provide motrin and ketorolac in identical packets labeled 1-88, after receiving the randomization strategy/number set from the research monitor. 2. REI physician on the protocol will screen patient for inclusion/exclusion from study at new patient consult or at future follow up visit when need for HSG is decided. 3. If patient pt screens eligible, discuss study. If elects participation then consent patient and randomize to group. 4. At time of scheduling HSG, patient will need to remind nursing that they are in HSG study. Nursing should also have the list of patients to reference when scheduling HSGs. Patients in the study will need to check in at the REI clinic 70 minutes prior to HSG in order to take their meds 60 minutes prior to scheduled procedure time. At same visit, REI RN will perform urine pregnancy test as previously scheduled. a. meds will be kept in a locked cabinet in the REI research office in opaque sealed envelopes. 5. Patient will then go check into Radiology for their HSG. 6. HSG will be performed per standard clinical protocol. The HSG will be performed by REI physicians and OB/GYN residents (who are rotating on REI), which are the current standard of practice. 7. A nurse or provider associated with the study will need to be at the HSG for the sole purpose of study assistance. The provider performing the HSG, the study personnel recording pain levels, and the fluro tech will not be aware of the type of pre-procedural medication the patient received. The nurse or provider of study personnel will do the following: 1. time the procedure from placement of speculum through deflation of catheter balloon and removal of catheter. Record time in seconds (can write mins:seconds and then convert later). 2. record who performed the procedure, if a tenaculum had to be used, and if an attending had to take over the procedure 3. help patient record pain scale marks on the VAS sheet at the designated time periods. 7. For clarity- there will be at least three providers at each HSG for study enrolled patients. 1. A provider who does the HSG 2. A fluoro technician to capture fluoro images for teh HSG 3. A study affialitied person to record pain scores for patient as above 8. At the conclusion of study recruitment, the blinded researchers will gain access to the subject ID's cohort status (ibuprofen vs ketorolac), and study analysis will be undertaken.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 88
Est. completion date January 1, 2023
Est. primary completion date October 15, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria: - English speaking - premenopausal females age 18-45 - patients currently undergoing HSG as part of routine work-up for infertility or subfertility, - - patients with negative urine pregnancy test within 24 hours of the scheduled procedure - patients having performance of HCG between menstrual cycle days 5-12n Exclusion Criteria: - Non-English speaking - patients with history of previous HSG performed - patients with contrast allergy or other contraindications to HSG - patients with contraindications to NSAID use - Patients with the following: - unwilling to consent - positive urine pregnancy test within 24 hours of the scheduled procedure - active renal or hepatic disease - chronic narcotic users - use of pain medications within 12 hours of the scheduled procedure - patients with chronic pain conditions (fibromyalgia, complex regional pain syndrome, etc.) - patients with unknown uterine anatomical pathology

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ibuprofen 800 mg oral
1 hour before HSG
Ketorolac 30mg oral
1 hour before HSG

Locations

Country Name City State
United States Madigan Army Medical Center Tacoma Washington

Sponsors (1)

Lead Sponsor Collaborator
Madigan Army Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pain during contrast infiltration Pain on Visual Analogue Scale (0-100) Between 0 seconds and 5 minutes
Secondary Pain at baseline (before procedure start) Pain on Visual Analogue Scale (0-100) Between 0 seconds and 5 minutes
Secondary Pain with HSG catheter placement Pain on Visual Analogue Scale (0-100) Between 0 seconds and 5 minutes
Secondary Pain at completion of HSG Pain on Visual Analogue Scale (0-100) Between 0 seconds and 5 minutes
Secondary Pain 5 minutes following HSG Pain on Visual Analogue Scale (0-100) 5 minutes after procedure
See also
  Status Clinical Trial Phase
Recruiting NCT05969574 - Is Decreased Ovarian Reserve Related to an Increased Number of Previous Early Miscarriages?
Recruiting NCT05358483 - PROspective Study of Mothers' and Infants' Social and Epidemiologic Determinants of Health
Recruiting NCT05969795 - Comparison of Live Birth Rate in Natural Cycle Single Euploid FET Versus Without Luteal Phase Support Phase 1
Recruiting NCT06051201 - Innovation for Small-scale Experiments: ReceptIVFity Test N/A
Completed NCT03177538 - Corifollitropin Alfa Combined With Menotropin Versus Follitropin and Lutropin Alfa in Expected Suboptimal Responders Phase 4
Completed NCT03638856 - Comparing Effectiveness of Oral Misoprostal for Cervical Priming in Hysteroscopy N/A
Completed NCT04052464 - The Study of the Implantation Window From Endometrial Biopsy With Gene Expression Methods
Withdrawn NCT04753736 - Immunophenotypage of RIF and RM Patients and Intrauterine Administration of PBMC N/A
Completed NCT03349905 - Deferred Versus Fresh Embryo Transfers N/A
Completed NCT05076981 - Progesterone Levels During Ovulation and Luteal Phase
Completed NCT04096027 - Cabergoline Before or After Oocyte Collection for Follicular Resolution Phase 4
Recruiting NCT05980091 - Optimal Timing of Euploid Day 6 Blastocyst Transfer in Frozen HRT Cycles, Day 6 or Day 7 of Progesterone Administration. Phase 1
Terminated NCT01933633 - Improved Fertility After Exercise in Overweight/Obese Women N/A
Completed NCT01202656 - Effect of Colony Stimulating Factor on Implantation and Pregnancy Rates Following IVF (in Vitro Fertilization) Phase 1/Phase 2
Terminated NCT01202643 - Effect of Colony Stimulating Factor on Poor Endometrial Development During IVF Phase 1/Phase 2
Completed NCT01408615 - A Post Marketing Observational Study of the Safety and Efficacy of Elonva (Corifollitropin Alfa) in General Practice (P08165)
Enrolling by invitation NCT05698550 - The Role of Erzhi Tiangui Formula in Expected POR Women Undergoing IVF-ET Phase 3
Not yet recruiting NCT03910582 - Personalized FET in RIF Patients With Displaced Dating N/A
Completed NCT05440019 - Evaluation of the Safety and Usability of the M3T Fertigo System and Its Calibration
Completed NCT05130125 - Retrospective Cohort Observational Study to Evaluate the Effectiveness and Safety of Fresh or Frozen Embryo Transfer